Physician profile
Frances Paola Velez-Bartolomei
NPI 1083099220
$10,567.78
in general payments reported to CMS, 2019-2025
15 companies · $5,584 in 2025
The $5,584 reported for 2025 was more than what 91% of Clinical Biochemical Genetics providers received nationally (typical 2025 total: $237).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.38 · 2022: $889 · 2023: $3,410 · 2024: $615 · 2025: $5,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,400 · Food and Beverage: $3,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,400.00 |
| Food and Beverage | $3,024.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,185.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $4,687.51 | 2025 | Sephience |
| Genzyme Corporation | $3,459.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $508.73 | 2022-2025 | Vpriv, Elaprase, Takhzyro |
| Biogen, INC. | $491.93 | 2021-2023 | Spinraza |
| Genentech USA, INC. | $406.09 | 2023-2025 | Evrysdi |
| Chiesi USA, INC. | $127.39 | 2025 | Elfabrio |
| Biomarin Pharmaceutical INC. | $125.86 | 2022 | |
| Sarepta Therapeutics, INC. | $120.54 | 2025 | |
| Mirum Pharmaceuticals, INC. | $112.90 | 2024 | Livmarli |
| Rhythm Pharmaceuticals, INC. | $109.26 | 2023 | Imcivree |
| Catalyst Pharmaceuticals, INC. | $104.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $100.64 | 2023 | |
| Acadia Pharmaceuticals INC | $92.36 | 2024 | Daybue |
| Pbg Puerto Rico LLC | $71.34 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $49.55 | 2023 | Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Velez-Bartolomei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.